Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06874751 · ClinicalTrials.gov registry record
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
A clinical trial, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 45,456
- Enrollment target
NCT06874751 is a clinical trial that has completed, run by Novo Nordisk A/S. The registered enrollment target is 45,456 participants.
The verdict
NCT06874751 has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 45,456 participants
- Enrollment target
Study Summary
This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide 2.4 mg in reducing the risk of CV and other obesity-related clinical outcomes.
Interventions
- OTHER No treatment given
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45,456 participants |
| Start Date | 2024-12-06 |
| Est. Completion | 2025-03-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06874751
The ClinicalTrials.gov registry entry for NCT06874751 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 45,456 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No treatment given is the first listed.
NCT06874751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06874751 about?
NCT06874751 is a clinical study titled "Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World". This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide 2.4 mg in reducing the risk of CV and other obesity-related clinical outc...
What is the current status of trial NCT06874751?
This trial is currently completed. The enrollment target is 45,456 participants. The study started on 2024-12-06. Estimated completion is 2025-03-28.
What interventions are being tested in trial NCT06874751?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT06874751?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.